Check-Cap Ltd. (CHEK)
USD 0.6
(-0.84%)
USD 0.6
(-0.84%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 19.28 Million USD | -3.73% |
| 2022 | 20.03 Million USD | 15.66% |
| 2021 | 17.32 Million USD | 24.33% |
| 2020 | 13.93 Million USD | -0.97% |
| 2019 | 14.06 Million USD | 27.17% |
| 2018 | 11.06 Million USD | 10.62% |
| 2017 | 10 Million USD | 10.36% |
| 2016 | 9.06 Million USD | -27.29% |
| 2015 | 12.46 Million USD | 159.11% |
| 2014 | 4.81 Million USD | 28.2% |
| 2013 | 3.75 Million USD | -3.67% |
| 2012 | 3.89 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q4 | 4.06 Million USD | 41.91% |
| 2023 Q2 | 6.06 Million USD | 25.01% |
| 2023 FY | 17.64 Million USD | -11.9% |
| 2023 Q1 | 4.85 Million USD | 15.07% |
| 2023 Q3 | 2.86 Million USD | -52.78% |
| 2022 FY | 20.03 Million USD | 15.66% |
| 2022 Q3 | 5.04 Million USD | 3.21% |
| 2022 Q4 | 4.21 Million USD | -16.45% |
| 2022 Q2 | 4.88 Million USD | -16.94% |
| 2022 Q1 | 5.88 Million USD | 5.5% |
| 2021 Q3 | 4.26 Million USD | 8.67% |
| 2021 Q2 | 3.92 Million USD | 10.29% |
| 2021 FY | 17.32 Million USD | 24.33% |
| 2021 Q4 | 5.57 Million USD | 30.85% |
| 2021 Q1 | 3.55 Million USD | -9.56% |
| 2020 Q4 | 3.93 Million USD | 8.32% |
| 2020 Q1 | 3.41 Million USD | -11.13% |
| 2020 Q2 | 2.94 Million USD | -13.75% |
| 2020 Q3 | 3.63 Million USD | 23.13% |
| 2020 FY | 13.93 Million USD | -0.97% |
| 2019 Q2 | 3.49 Million USD | 10.43% |
| 2019 FY | 14.06 Million USD | 27.17% |
| 2019 Q3 | 3.56 Million USD | 2.0% |
| 2019 Q1 | 3.16 Million USD | -8.79% |
| 2019 Q4 | 3.84 Million USD | 7.94% |
| 2018 Q3 | 2.8 Million USD | 4.28% |
| 2018 FY | 11.06 Million USD | 10.62% |
| 2018 Q4 | 3.46 Million USD | 23.8% |
| 2018 Q2 | 2.68 Million USD | 27.65% |
| 2018 Q1 | 2.1 Million USD | 2.28% |
| 2017 Q2 | 2.8 Million USD | 1.59% |
| 2017 Q3 | 7.94 Million USD | 182.97% |
| 2017 Q4 | 2.05 Million USD | -74.09% |
| 2017 FY | 10 Million USD | 10.36% |
| 2017 Q1 | 2.76 Million USD | 13.52% |
| 2016 Q3 | 1.75 Million USD | -11.19% |
| 2016 FY | 9.06 Million USD | -27.29% |
| 2016 Q1 | 2.9 Million USD | -5.01% |
| 2016 Q2 | 1.97 Million USD | -31.9% |
| 2016 Q4 | 2.43 Million USD | 38.77% |
| 2015 Q2 | 2.56 Million USD | -33.56% |
| 2015 Q1 | 3.86 Million USD | 124.06% |
| 2015 Q4 | 3.05 Million USD | 1.36% |
| 2015 Q3 | 3.01 Million USD | 17.29% |
| 2015 FY | 12.46 Million USD | 159.11% |
| 2014 Q3 | 881 Thousand USD | -20.77% |
| 2014 Q1 | 1.09 Million USD | 64.58% |
| 2014 Q2 | 1.11 Million USD | 1.83% |
| 2014 Q4 | 1.72 Million USD | 95.8% |
| 2014 FY | 4.81 Million USD | 28.2% |
| 2013 Q2 | 953 Thousand USD | -9.24% |
| 2013 Q4 | 663.5 Thousand USD | 0.0% |
| 2013 FY | 3.75 Million USD | -3.67% |
| 2013 Q1 | 1.05 Million USD | 0.0% |
| 2013 Q3 | 663.5 Thousand USD | -30.38% |
| 2012 FY | 3.89 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bionano Genomics, Inc. | 148.99 Million USD | 87.055% |
| Prenetics Global Limited | 60.73 Million USD | 68.245% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -18.529% |
| CareDx, Inc | 277.76 Million USD | 93.056% |
| Exact Sciences Corporation | 2.06 Billion USD | 99.064% |
| Exagen Inc. | 52.29 Million USD | 63.117% |
| Inotiv, Inc. | 246.9 Million USD | 92.188% |
| Guardant Health, Inc. | 901.62 Million USD | 97.861% |
| Biodesix, Inc. | 77.41 Million USD | 75.088% |
| BioNexus Gene Lab Corp. | 3.92 Million USD | -391.628% |
| Precipio, Inc. | 13.63 Million USD | -41.421% |
| iSpecimen Inc. | 16.27 Million USD | -18.49% |
| Natera, Inc. | 938.98 Million USD | 97.946% |
| Aspira Women's Health Inc. | 24.11 Million USD | 20.017% |
| Standard BioTools Inc. | 113.48 Million USD | 83.005% |
| 23andMe Holding Co. | 420.73 Million USD | 95.416% |
| Castle Biosciences, Inc. | 242.78 Million USD | 92.056% |
| Personalis, Inc. | 128.14 Million USD | 84.949% |
| Aclaris Therapeutics, Inc. | 110.52 Million USD | 82.55% |
| Applied DNA Sciences, Inc. | 16.48 Million USD | -16.985% |
| OpGen, Inc. | 30.65 Million USD | 37.09% |
| T2 Biosystems, Inc. | 41.49 Million USD | 53.519% |
| Myriad Genetics, Inc. | 600.1 Million USD | 96.786% |
| ICON Public Limited Company | 755.64 Million USD | 97.448% |
| NeoGenomics, Inc. | 341.25 Million USD | 94.348% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -18.529% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 98.235% |
| RadNet, Inc. | 268.87 Million USD | 92.827% |
| MDxHealth SA | 71.25 Million USD | 72.933% |
| Psychemedics Corporation | 11.33 Million USD | -70.169% |
| Illumina, Inc. | 3.81 Billion USD | 99.494% |
| Twist Bioscience Corporation | 354.18 Million USD | 94.554% |
| DarioHealth Corp. | 62.17 Million USD | 68.978% |
| Fulgent Genetics, Inc. | 171.9 Million USD | 88.78% |
| Sera Prognostics, Inc. | 39.91 Million USD | 51.682% |
| ENDRA Life Sciences Inc. | 10.52 Million USD | -83.324% |
| OPKO Health, Inc. | 574.68 Million USD | 96.644% |
| Medpace Holdings, Inc. | 187.68 Million USD | 89.723% |
| Neogen Corporation | 405.23 Million USD | 95.241% |
| Intelligent Bio Solutions Inc. | 11.7 Million USD | -64.722% |
| Prenetics Global Limited | 60.73 Million USD | 68.245% |
| Mainz Biomed B.V. | 27.15 Million USD | 28.973% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -120.05% |
| Trinity Biotech plc | 46.49 Million USD | 58.518% |
| Neuronetics, Inc. | 82.25 Million USD | 76.553% |
| Sotera Health Company | 300.46 Million USD | 93.581% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -120.05% |